PTCT - PTC Therapeutics, Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD

PTC Therapeutics, Inc.

100 Corporate Court
South Plainfield, NJ 07080
United States

Full Time Employees366

Key Executives

NameTitlePayExercisedYear Born
Dr. Stuart W PeltzCo-Founder, CEO & Exec. Director887.6kN/A1960
Dr. Allan Steven JacobsonCo-Founder, Chairman of Scientific Advisory Board & Director135kN/A1946
Dr. Neil Almstead Ph.D.Exec. VP of Research, Pharmaceutical Operations & Technology574.45k10.3k1967
Mr. Mark Elliott BouldingChief Legal Officer, EVP & Sec.579.23kN/A1961
Ms. Christine UtterPrincipal Financial & Accounting Officer and TreasurerN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders. The company offers Translarna (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients; and Emflaza (deflazacort) for treating Duchenne muscular dystrophy. It is developing Translarna, which is in Phase II clinical study for the treatment of nonsense mutation aniridia and nonsense mutation Dravet syndrome/CDKL5; and RG7916 for the treatment of patients with spinal muscular atrophy, as well as PTC596, an orally bioavailable and potent small molecule that has completed Phase I study, which targets solid tumor cell populations by reducing the activity and amount of BMI1. The company has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., and the Spinal Muscular Atrophy Foundation to develop and commercialize compounds identified under its spinal muscular atrophy sponsored research program; and research collaboration with Massachusetts General Hospital for the treatment of rare genetic disorders resulting from pre-mRNA. PTC Therapeutics, Inc. was founded in 1998 and is headquartered in South Plainfield, New Jersey.

Corporate Governance

PTC Therapeutics, Inc.’s ISS Governance QualityScore as of March 1, 2018 is 7. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 7; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.